Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 1

1(14.3%)

N/A

1(14.3%)

Phase 3

1(14.3%)

Phase 4

1(14.3%)

7Total

Phase 2(3)

Phase 1(1)

N/A(1)

Phase 3(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT01865162Phase 1Completed

Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study

Role: lead

NCT05517954Unknown

Cortical Excitability in Post-traumatic Epilepsy

Role: lead

NCT04879433Unknown

Prospective Open-label Evaluation of Cenobamate Adjunctive Treatment of Adults With Refractory Focal Epilepsy

Role: lead

NCT02302235Phase 2Completed

Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study

Role: lead

NCT03652649Not ApplicableUnknown

Treatment of Type 2 Diabetes With Ketogenic Diet

Role: lead

NCT02069197Phase 2Unknown

Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea

Role: lead

NCT01906398Phase 2Unknown

Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy

Role: lead

NCT02726867Phase 3Withdrawn

Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus

Role: lead

NCT02727101Phase 4Terminated

Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.

Role: lead

All 9 trials loaded